These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 526925)

  • 61. Cytosine arabinoside (NSC-63878)--clinical brochure.
    Livingston RB; Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
    [No Abstract]   [Full Text] [Related]  

  • 62. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
    Lincoln T; Morrison P; Aroesty J; Carter G
    Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside, in a sub-line of the L1210 murine leukemia.
    Kessel D; Shurin SB
    Biochim Biophys Acta; 1968 Sep; 163(2):179-87. PubMed ID: 5686275
    [No Abstract]   [Full Text] [Related]  

  • 64. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2.
    Bhuyan BK; Fraser TJ; Day KJ
    Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
    Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
    Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia.
    Edelstein M; Valeriote F; Vietti T
    Cancer Treat Rep; 1978 Apr; 62(4):547-8. PubMed ID: 657151
    [No Abstract]   [Full Text] [Related]  

  • 67. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.
    Juliano RL; McCullough HN
    J Pharmacol Exp Ther; 1980 Aug; 214(2):381-7. PubMed ID: 7391983
    [TBL] [Abstract][Full Text] [Related]  

  • 68. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
    Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi JI; Ishida T
    Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of tumor cell growth in vitro and in vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles.
    Sautereau AM; Cros S; Tocanne JF
    Biopharm Drug Dispos; 1986; 7(4):357-71. PubMed ID: 3768491
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Disposition of arabinosylcytosine (NSC-63878) and 6-THIOGUANINE (NSC-752) in solid L1210 leukemia tumor-bearing mice.
    Pittillo RF; Woolley C
    Cancer Chemother Rep; 1973; 57(3):275-89. PubMed ID: 4201593
    [No Abstract]   [Full Text] [Related]  

  • 71. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.
    Kim S; Kim DJ; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(4):307-10. PubMed ID: 3594716
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
    Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
    J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Liposome-cell interactions. A study of the interactions of liposomes containing entrapped anti-cancer drugs with the EMT6, S49 and AE1 (transport-deficient) cell lines.
    Allen TM; McAllister L; Mausolf S; Gyorffy E
    Biochim Biophys Acta; 1981 May; 643(2):346-62. PubMed ID: 7225387
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antitumor activity of lipophilic prodrugs of mitomycin C entrapped in liposome or O/W emulsion.
    Sasaki H; Takakura Y; Hashida M; Kimura T; Sezaki H
    J Pharmacobiodyn; 1984 Feb; 7(2):120-30. PubMed ID: 6427444
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878) in mice.
    Liss RH; Neil GL
    Cancer Chemother Rep; 1975; 59(3):501-13. PubMed ID: 1203880
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Temperature-dependent drug release from large unilamellar liposomes.
    Magin RL; Niesman MR
    Cancer Drug Deliv; 1984; 1(2):109-17. PubMed ID: 6549573
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cytosine arabinoside uptake by tumour cells in vitro.
    Mulder JH; Harrap KR
    Eur J Cancer (1965); 1975 May; 11(5):373-9. PubMed ID: 1171764
    [No Abstract]   [Full Text] [Related]  

  • 78. Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept.
    Gregoriadis G
    Ann N Y Acad Sci; 1978; 308():343-70. PubMed ID: 100040
    [No Abstract]   [Full Text] [Related]  

  • 79. [Liposomes--carriers of cytostatic preparations].
    Afonin NI; Oksinoĭd OE; Ermakova LN
    Gematol Transfuziol; 1984 Nov; 29(11):43-6. PubMed ID: 6085059
    [No Abstract]   [Full Text] [Related]  

  • 80. ACTIVITY OF SELECTED COMPOUNDS IN SUBLINE OF LEUKEMIA L1210 RESISTANT TO CYTOSINE ARABINOSIDE (NSC-63878).
    WODINSKY I; KENSLER CJ
    Cancer Chemother Rep; 1964 Dec; 43():1-3. PubMed ID: 14250647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.